

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

**PUBLIC ANNOUNCEMENT**



(Please scan this QR Code to view the Draft Red Herring Prospectus)

## REDNEX PHARMACEUTICALS LIMITED

Our Company was originally incorporated as a Private Limited Company under the name "Rednex Pharmaceuticals Private Limited" on December 29, 2020 under the provisions of the Companies Act, 2013 with the Registrar of Companies, Ahmedabad bearing CIN: U24304GJ2020PTC119176. Subsequently, our Company was converted into a Public Limited Company vide Special Resolution passed by the Shareholders at the Extraordinary General Meeting, held on December 30, 2024 and consequently, the name of our Company was changed from "Rednex Pharmaceuticals Private Limited" to "Rednex Pharmaceuticals Limited" vide a fresh certificate of incorporation dated January 21, 2025 issued by the Registrar of Companies, Central Processing Centre bearing CIN: U24304GJ2020PLC119176. For further details of Incorporation, change of registered office of our Company, please refer to chapter titled "**History and Corporate Structure**" beginning on page 146 of the Draft Red Herring Prospectus.

**Registered Office:** Survey No. 586 and 231, Near SKF Bearing, Bavla Bagodara N.H 8A, Kerala, Taluka: Bavla, Ahmedabad, Gujarat, India, 382220.

**Tel. No.:** +91-83201-31437, **E-mail:** : info@rednexpharma.com ; Website: https://rednexpharma.com/

**Contact Person:** Rima Amitbhai Dalal Company Secretary & Compliance Officer

**CIN:** U24304GJ2020PLC119176

### OUR PROMOTERS: CHETAN RUGNATHBHAI MATHOLIYA, JAYESHKUMAR AMARSHIBHAI SABAVA AND AKASHBHAI MANSUKHBHAI GANGADIYA

**"THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF BSE ("BSE SME")."**

### THE ISSUE

**INITIAL PUBLIC OFFER OF UPTO 27,36,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH (THE "EQUITY SHARES") OF REDNEX PHARMACEUTICALS LIMITED ("OUR COMPANY" OR "THE ISSUER") AT AN ISSUE PRICE OF ₹ 10 PER EQUITY SHARE FOR CASH, AGGREGATING UP TO ₹10 LAKHS ("PUBLIC ISSUE") OUT OF WHICH 10 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ 10 PER EQUITY SHARE FOR CASH, AGGREGATING ₹ 10 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 10 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ 10 PER EQUITY SHARE FOR CASH, AGGREGATING UPTO ₹10 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE 26.34% AND 10% RESPECTIVELY OF THE POST- ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.**

**THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY IN CONSULTATION WITH THE BRLM AND WILL BE ADVERTISED IN 10 EDITION OF 10 (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER) AND 10 EDITION OF 10 (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER, AND GUJARATI EDITION OF 10), REGIONAL NEWSPAPER ( WHERE OUR REGISTERED OFFICE IS LOCATED), AT LEAST TWO WORKING DAYS PRIOR TO THE BID/ ISSUE OPENING DATE AND SHALL BE MADE AVAILABLE TO THE SME PLATFORM OF BSE LIMITED ("BSE LIMITED") FOR THE PURPOSES OF UPLOADING ON THEIR WEBSITE.**

In case of any revision in the Price Band, the Bid/Issue Period shall be extended for at least three additional Working Days after such revision of the Price Band, subject to the total Bid/Issue Period not exceeding ten Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company, for reasons to be recorded in writing extend the Bid/Issue Period for a minimum of one Working Day, subject to the Bid/Issue Period not exceeding ten Working Days. Any revision in the Price Band, and the revised Bid/Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges by issuing a press release and also by indicating the change on the website of the BRLM and at the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and Sponsor Bank.

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders (of which one third of the Non-Institutional Portion shall be reserved for Bidders with an application size of more than two lots and up to such lots equivalent to not more than ₹10 lakhs and two-thirds of the Non-Institutional Portion shall be reserved for Bidders with an application size exceeding ₹ 10 lakhs) and under-subscription in either of these sub-categories of Non-Institutional Portion may be allocated to Bidders in the other subcategory of Non-Institutional Portion, subject to valid Bids being received at or above the Issue Price and not less than 35% of the Net Issue shall be available for allocation to Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilize the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of Individual Bidders using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "**Issue Procedure**" beginning on page 273 of the Draft Red Herring Prospectus.

This public announcement is made in compliance with the provisions of Regulation 247(2) of the SEBI ICDR Regulations, to inform the public that our Company is proposing to undertake, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, an initial public offer of its Equity Shares of face value of ₹ 10 each pursuant to the Issue and the Draft Red Herring Prospectus dated September 30, 2025 has been filed with the SME Platform of BSE ("BSE SME") on September 30, 2025. The Draft Red Herring Prospectus filed with BSE SME shall be made public, for comments, if any, for a period of at least 21 days from the date of filing, by hosting it on the website of BSE SME at [https://www.bsesme.com/download/399519/SME\\_IPO%20InPrinciple/RednexpharmaceuticalsDRHP\\_20250930190141.pdf](https://www.bsesme.com/download/399519/SME_IPO%20InPrinciple/RednexpharmaceuticalsDRHP_20250930190141.pdf), on the website of the BRLM at [www.hemsecurities.com](http://www.hemsecurities.com) and also on the website of the Company <https://rednexpharma.com/>. Our Company invites the public to give comments on the Draft Red Herring Prospectus filed with BSE SME with respect to disclosures made in the Draft Red Herring Prospectus. The public is requested to send a copy of the comments to the Company Secretary & Compliance Officer of our Company, and/or to the BRLM at their respective addresses mentioned below. All comments must be received by our Company and/or Company Secretary & Compliance Officer of our Company and/or to the BRLM in relation to the Issue on or before 5.00 p.m. on the 21st day from the aforementioned date of filing of the Draft Red Herring Prospectus with BSE SME.

Investments in Equity and Equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue including the risks involved. The Equity Shares issued in the Issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the Draft Red Herring Prospectus. Specific attention of the investors is invited to the section "**Risk Factors**" beginning on page 27 of the Draft Red Herring Prospectus.

Any decision to invest in the equity shares described in the Draft Red Herring Prospectus may only be taken after a Red Herring Prospectus has been filed with the ROC and must be made solely on the basis of such Red Herring Prospectus as there may be material changes in the Red Herring Prospectus from the Draft Red Herring Prospectus. The equity shares, when offered through the Red Herring Prospectus, are proposed to be listed on the BSE Limited ("BSE SME"). For details of the share capital and capital structure of our Company and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them of our Company, see "**Capital Structure**" beginning on page 68 of the Draft Red Herring Prospectus. The liability of the members of our Company is limited. For details of the main objects of our Company as contained in our Memorandum of Association, see "**History and Corporate Structure**" beginning on page 146 of the Draft Red Herring Prospectus.

The BRLM associated with the Issue has handled 69 Public Issues in the past three years, out of which 3 issue was closed below the Issue/ Offer Price on listing date:

Name of BRLM	Total Issue		Issue closed below IPO Price on listing date
	Mainboard	SME	
Hem Securities Limited	2	67	3 (SME)

#### BOOK RUNNING LEAD MANAGER TO THE ISSUE

#### REGISTRAR TO THE ISSUE



#### HEM SECURITIES LIMITED

**Address:** 904, A Wing, Naman Midtown, Senapati Bapat Marg, Elphinstone Road, Lower Parel, Mumbai-400013, Maharashtra, India


**Tel. No.:** +91- 22- 49060000;

**Email:** ib@hemsecurities.com

**Investor Grievance Email:** redressal@hemsecurities.com

**Website:** www.hemsecurities.com

**Contact Person:** Roshni Lahoti ; **SEBI Regn. No.** INM000010981



#### BIGSHARE SERVICES PRIVATE LIMITED

**Address:** Office No. S6-2, 6th floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri East, Mumbai- 400093, Maharashtra, India

**Telephone:** +91 022-6263 8200 ; **Email:** ipo@bigshareonline.com

**Investor Grievance Email:** investor@bigshareonline.com

**Website:** www.bigshareonline.com

**Contact Person:** Mr. Babu Raphael C.

**SEBI Registration Number:** INR000001385 ; **CIN:** U99999MH1994PTC076534

#### COMPANY SECRETARY & COMPLIANCE OFFICER

#### REDNEX PHARMACEUTICALS LIMITED

Rima Amitbhai Dalal

**Registered Office:** Survey No. 586 and 231, Near SKF Bearing, Bavla Bagodara N.H 8A, Kerala, Taluka: Bavla, Ahmedabad, Gujarat, India, 382220.

**E-mail:** cs@rednexpharma.com, **Tel.:** +91- 83201-31437, **Website:** https://rednexpharma.com/

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Draft Red Herring Prospectus.

#### REDNEX PHARMACEUTICALS LIMITED

On behalf of the Board of Directors

Sd/-

Rima Amitbhai Dalal

Company Secretary and Compliance Officer

**Place:** Ahmedabad, Gujarat

**Date:** October 01, 2025

**Disclaimer:** Rednex Pharmaceuticals Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Draft Red Herring Prospectus on September 30, 2025. The Draft Red Herring Prospectus is available on the website of BSE SME at [https://www.bsesme.com/download/399519/SME\\_IPO%20InPrinciple/RednexpharmaceuticalsDRHP\\_20250930190141.pdf](https://www.bsesme.com/download/399519/SME_IPO%20InPrinciple/RednexpharmaceuticalsDRHP_20250930190141.pdf) and is available on the websites of the BRLM at [www.hemsecurities.com](http://www.hemsecurities.com) and also on the website of the Company <https://rednexpharma.com/>. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, see the section titled "**Risk Factors**" beginning on page 27 of the Draft Red Herring Prospectus. Potential investors should not rely on the Draft Red Herring Prospectus for making any investment decision.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "**Securities Act**") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

# Navigate markets with focused insight.

Get daily sector trends, market movers, and sharp insights — every day with **The Compass** in Business Standard.

To book your copy, SMS reachbs to **57575** or email **order@bsmail.in**



# Business Standard Insight Out

# मिडकैप फंड: अच्छे मूल्यांकन और दमदार आय वृद्धि की संभावनाओं के साथ करें निवेश

सर्वजित के सेन

**इक्विटी** बाजार की मिडकैप श्रेणी अक्सर निवेशकों का ध्यान आकर्षित करती रहती है। म्यूचुअल फंडों के संगठन एसोसिएशन ऑफ म्यूचुअल फंड्स इन इंडिया (एम्फो) के अनुसार, अगस्त 2025 के दौरान मिडकैप फंड में 5,330 करोड़ रुपये का निवेश दर्ज किया गया जो किसी एक महीने का अब तक का सर्वाधिक निवेश है।

मिरे एसेट इन्वेस्टमेंट मैनेजर्स (इंडिया) के वरिष्ठ फंड मैनेजर अंकित जैन ने कहा, 'पिछले 4-5 वर्षों के दौरान मिडकैप फंड में निवेश इक्विटी में शुद्ध निवेश का 8 से 9 फीसदी पर

बरकरार रहा है। अगस्त में यह करीब 11 फीसदी था। इससे स्पष्ट तौर पर पता चलता है कि इस श्रेणी में निवेशकों का भरोसा बढ़ा है और उनका नजरिया परिपक्व हुआ है जहां मध्यावधि में मजबूत आय वृद्धि की क्षमता है।' मिडकैप योजनाएं अपनी कुल निधि का कम से कम 65 फीसदी रकम उन कंपनियों में निवेश करती हैं जिनकी रैंकिंग बाजार पूंजीकरण के लिहाज से 101 से 250 के बीच है। 31 अगस्त, 2025 तक कुल 67 मिडकैप योजनाओं ने 4.44 लाख करोड़ रुपये की परिसंपत्तियों का प्रबंधन किया।

**लंबी अवधि में फायदेमंद**

बाजार में अनिश्चितता के दौरान काफी अधिक

निवेश अतार्किक लग सकता है, लेकिन यह निवेशकों की परिपक्वता और सोच समझकर जोखिम उठाने की इच्छा को दर्शाता है।

**वृद्धि की क्षमता**

अर्थव्यवस्था का विस्तार होने के साथ ही कई मिडकैप फर्म दमदार बहीखाते एवं मजबूत आय वाली बड़ी कंपनी के रूप में विकसित होती हैं। अपने क्षेत्र की कई अग्रणी कंपनियां इसी श्रेणी से आती हैं।

**मूल्यांकन के साथ सहजता**

बाजार में हालिया गिरावट ने मूल्यांकन को निवेश के लिए काफी बेहतर स्तर पर ला दिया है। जैन ने



कहा, 'पिछले एक साल के गिरावट के कारण मूल्यांकन काफी आकर्षक हो चुका है। वह सितंबर 2024 में प्राइस-टू-अर्निंग (पीई) के करीब 35 गुना से अब 28 गुना रह गया है जो

ऐतिहासिक औसत से करीब 15 फीसदी अधिक है। यह भविष्य में आय वृद्धि की क्षमता के लिहाज से बिल्कुल उचित है।'

**उतार-चढ़ाव का जोखिम**

बाजार में गिरावट के दौरान मिडकैप श्रेणी में लाजकैप के मुकाबले तेज गिरावट आती है। ध्वन ने कहा, 'इसमें गिरते बाजार में भारी गिरावट का जोखिम रहता है। ऐतिहासिक तौर पर देखा जाए तो बाजार में गिरावट के दौरान इसमें 40 से 50 फीसदी तक की गिरावट दिख सकती है। घरेलू सिस्टमेटिक इन्वेस्टमेंट प्लान (एसआईपी) में निवेश प्रवाह दमदार रहने और बेहतर स्थिरता की संभावना रहती है।

**जोखिम लेने वालों के लिए उपयुक्त**

मिडकैप फंड उन निवेशकों के लिए उपयुक्त हैं जिनकी जोखिम लेने की क्षमता अधिक है और जो लंबे समय के लिए निवेश करना चाहते हैं। ध्वन ने कहा, 'कम अधिक के लिए निवेश करने वालों अथवा उतार-चढ़ाव के प्रति कम सहनशीलता लोगों को मिडकैप फंड से बचना चाहिए। आदर्श तौर पर इसमें कम से कम 10 वर्षों के लिए निवेश की सलाह दी जाती है। एक खास इक्विटी पोर्टफोलियो के तहत मिडकैप में करीब 20 फीसदी आवंटन हो सकता है, जहां आक्रामक निवेशक मूल्यांकन कम होने पर 40 फीसदी तक निवेश कर सकते हैं।'

पहले से तैयार या निर्माणाधीन मकान

## जरूरत और क्षमता देखने के बाद लें घर



संजीव सिन्हा

भारत में पहले से तैयार मकानों की मांग में गिरावट आई है। एनारॉक के हालिया मकान खरीदार धारणा सर्वेक्षण (होमबायर सेंटीमेंट सर्वे) से इसका पता चला है। इस साल की पहली छमाही में बने मकानों और नई पेशकशों की मांग अनुपात घटकर 16:29 रह गया है। यह वैश्विक महामारी वाले साल से बड़ा उलटफेर है, तब 2020 की पहली छमाही में पहले से तैयार मकानों का दबदबा था और अनुपात भी 46:18 था।

**यह उलटफेर क्यों**

पहले से बने मकानों की लोकप्रियता तब थी जब बाजार में छोटे, कम रकम वाले डेवलपर थे, जिनकी परियोजनाओं में देरी होती थी या पूरी नहीं हो पाती थीं। एनारॉक समूह के उपाध्यक्ष संतोष कुमार कहते हैं, 'खरीदारों ने पहले से बने मकानों को तब तक नहीं देखा कि वह देख सकें और रहने के वास्तु तुरंत चले जाएं। भले ही इसके लिए उन्हें अधिक कीमत चुकानी पड़े। कोविड के बाद प्रतिष्ठित और सूचीबद्ध डेवलपरों का बोलबाला हो गया और खरीदार भी उनकी परियोजनाओं में निवेश करने में संकोच नहीं करते हैं।'

**पहले से तैयार मकानों का नफा-नुकसान**

कुमार के मुताबिक, पहले से तैयार मकानों का एक बड़ा फायदा है कि आप जो देखते हैं वही आपको मिलता है। इसके अलावा, आपको जब तक मकान नहीं मिलता है तब तक आपको किराया नहीं देना पड़ता है, देरी होने के झंझट से मुक्ति मिली रहती है और आप जब चाहे उसमें रहने के लिए जा सकते हैं। दूसरी ओर, ऐसे मकानों की कीमत आमतौर पर निर्माणाधीन मकानों के मुकाबले 15 से 20 फीसदी अधिक होता है। इसमें विकल्प भी सीमित होते हैं और इनकी कीमत भी धीरे-धीरे बढ़ती है। एक्सपीरियल्ड इंडिया के प्रेसिडेंट और कंटी हेड सैम चोपड़ा कहते हैं, 'जो लोग निश्चितता चाहते हैं उनके लिए यह सही है। मगर गुरुग्राम और पुणे जैसे तेजी से बदलते बाजार में नई पेशकश के साथ मूल्य का अंतर बढ़ रहा है।'

**निर्माणाधीन मकानों का नफा-नुकसान**

निर्माणाधीन मकानों की लागत कम होती है। आप धीरे-धीरे कर के भी रकम चुकते हैं, जिससे आप पर आर्थिक बोझ नहीं पड़ता है। इसके अलावा, इसमें नए इंफ्रास्ट्रक्चर अनुपालन और स्मार्ट होम की सुविधाएं भी मिल जाती हैं। चोपड़ा

**मकान खरीदने से पहले ध्यान रखें**

■ अगर आपको तुरंत मकान चाहिए और आप पहले दिन से ही ईएमआई चुका सकते हैं तो पहले से बना मकान खरीद लें

■ मगर आप धीरे-धीरे रकम चुकाना चाहते हैं और मकान बनने का इंतजार कर सकते हैं तो आपको निर्माणाधीन मकानों का रुख करना चाहिए

■ बिल्डर का रिकॉर्ड, रेरा की स्थिति, बिल्डर के पास कितनी रकम है उसकी उचित जांच-पड़ताल करें

■ देरी होने की आशंका पर किराया और ईएमआई दोनों के लिए बजट बनाएं

■ जैसे-जैसे मकान बने वैसे-वैसे भुगतान करें

■ निर्माण कार्यों की निगरानी करें

■ उभरते हुए बुनियादी ढांचा केंद्रों में प्रतिस्पर्धी मूल्य वाली परियोजना चुनें

बताते हैं, 'इनकी कीमतें बढ़ने की काफी गुंजाइश रहती है। इन मकानों को वस्तु एवं सेवा कर (जीएसटी) से राहत मिलती है और अनिवासी भारतीयों को थोड़ा ज्यादा फायदा होता है क्योंकि रुपये में गिरावट आने पर उनकी डॉलर वाली आय बढ़ जाती है।'

राइज इन्फ्रावैचर्स के उपाध्यक्ष (सेल्स) मोहित गावरी कहते हैं, 'निर्माण से जुड़े भुगतान और पेशकश वाले ऑफर से ऐसे मकानों को खरीदने पर आर्थिक कठिनाइयां कम होती हैं। उन्होंने कहा कि रेरा लागू होने से अब देरी का जोखिम भी कम हो गया है। हालांकि, निर्माणाधीन संपत्तियों में कई खामियां भी होती हैं। कुमार बताते हैं, 'इनमें मकान मिलने तक किराया देना होता है। इसके अलावा, निर्माण और देरी का भी जोखिम होता है, जो आमतौर पर स्थानीय डेवलपरों के साथ ज्यादा देखने को मिलता है। साथ ही मकान में जाने में देरी होती है और जीएसटी शुल्क भी शामिल होता है। हालांकि, इसे अक्सर डेवलपर चुकाते हैं।'

**कैसे करें चयन**

निर्माणाधीन मकान उन खरीदारों के लिए सही है, जिनके पास पहले से रहने के लिए जगह है। जिन लोगों ने किसी भरोसेमंद डेवलपर से मकान बुक कराया है, जो बेहतर सुविधाएं चाहते हैं और जिन्हें निवेश पर अधिक रिटर्न की चाहत होती है। कुमार कहते हैं, 'पहले से बने मकान तब सही होते हैं जब संपत्ति अनुठी हो और सभी जरूरतों को पूरा करती हो। अधिक कीमत चुकाना कोई चिंता की बात नहीं है अगर आप तुरंत मकान में रहना चाहते हैं। चोपड़ा का कहना है, 'नोएडा, द्वारका एक्सप्रेसवे और हैदराबाद जैसे बुनियादी ढांचे से समृद्ध बाजार में निर्माणाधीन मकान काफी

लोकप्रिय हैं, जबकि मुंबई में कमी के कारण पहले से बने मकानों की मांग रहती है। हालांकि, जीएसटी दरों में कटौती ने लागत के अंतर को कम किया है, फिर भी पसंद शहर में आपूर्ति और आपकी आर्थिक क्षमता पर ही निर्भर करता है।'

**क्या चुनें निवेशक**

निवेशकों को निर्माणाधीन मकानों पर अक्सर बढ़त मिलती है। प्रमाणित वित्तीय योजनाकार और हम फौजी इनीशिएटिव के मुख्य कार्य अधिकारी संजीव गोविल ने कहा, 'निर्माणाधीन मकानों पर कीमतों का फायदा मिलता है, बुनियादी ढांचे से जुड़ी मूल्य वृद्धि का लाभ मिलता है और समय के साथ बेहतर लाभ भी मिलता है। पहले से तैयार मकान तभी सार्थक होते हैं जब आपको तुरंत किराया लेना होता है अथवा आय उत्पादक परिसंपत्तियों में विविधता लानी होती है। गावरी ने कहा कि पहले से बने मकानों में कीमतें बढ़ने की गुंजाइश कम होती है, क्योंकि मूल्यवृद्धि का अधिकांश हिस्सा पहले ही पूरा हो चुका होता है।'

**ऋणधारकों के लिए सलाह**

पहले से बने मकानों के मामले में खरीदारों को मूलधन और ब्याज पर कर लाभ तुरंत मिल जाता है। गोविल कहते हैं, 'निर्माणाधीन मकानों में आपको ये लाभ तब तक नहीं मिलते हैं, जब तक मकान आपको न मिल जाए। हालांकि, निर्माण पूर्व ब्याज का दावा आप बाद में भी कर सकते हैं।'

पहले से बने मकान उन ऋणधारकों के लिए सही है, जो रहने के लिहाज से तुरंत मकान लेना चाहते हैं, पहले दिन से ही ईएमआई चुका सकते हैं और कर राहत भी तुरंत लेना चाहते हैं।

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

**PUBLIC ANNOUNCEMENT**



## REDNEX PHARMACEUTICALS LIMITED

Our Company was originally incorporated as a Private Limited Company under the name "Rednex Pharmaceuticals Private Limited" on December 29, 2020 under the provisions of the Companies Act, 2013 with the Registrar of Companies, Ahmedabad bearing CIN: U24304GJ2020PTC119176. Subsequently, our Company was converted into a Public Limited Company vide Special Resolution passed by the Shareholders at the Extraordinary General Meeting, held on December 30, 2024 and consequently, the name of our Company was changed from "Rednex Pharmaceuticals Private Limited" to "Rednex Pharmaceuticals Limited" vide a fresh certificate of incorporation dated January 21, 2025 issued by the Registrar of Companies, Central Processing Centre bearing CIN: U24304GJ2020PLC119176. For further details of Incorporation, change of registered office of our Company, please refer to chapter titled "**History and Corporate Structure**" beginning on page 146 of the Draft Red Herring Prospectus.

Registered Office: Survey No. 586 and 231, Near SKF Bearing, Bavla Bagodara N.H 8A, Kerala, Taluka: Bavla, Ahmedabad, Gujarat, India, 382220.

Tel. No.: +91-83201-31437, E-mail: info@rednexpharma.com; Website: https://rednexpharma.com/

Contact Person: Rima Amitbhai Dalal Company Secretary & Compliance Officer

CIN: U24304GJ2020PLC119176

**OUR PROMOTERS: CHETAN RUGNATHBHAI MATHOLIYA, JAYESHKUMAR AMARSHIBHAI SABAVA AND AKASHBHAI MANSUKHBHAI GANGADIYA**

**"THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF BSE ("BSE SME")."**

### THE ISSUE

INITIAL PUBLIC OFFER OF UPTO 27,36,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH (THE "EQUITY SHARES") OF REDNEX PHARMACEUTICALS LIMITED ("OUR COMPANY" OR "THE ISSUER") AT AN ISSUE PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING UP TO ₹[●] LAKHS ("PUBLIC ISSUE") OUT OF WHICH [●] EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING ₹ [●] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF [●] EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING UPTO ₹ [●] LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE 26.34% AND [●] % RESPECTIVELY OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DETERMINED BY OUR COMPANY IN CONSULTATION WITH THE BRLM AND WILL BE ADVERTISED IN [●] EDITION OF [●] (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER) AND [●] EDITION OF [●] (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER, AND GUJARATI EDITION OF [●]), REGIONAL NEWSPAPER ( WHERE OUR REGISTERED OFFICE IS LOCATED), AT LEAST TWO WORKING DAYS PRIOR TO THE BID/ISSUE OPENING DATE AND SHALL BE MADE AVAILABLE TO THE SME PLATFORM OF BSE LIMITED ("BSE LIMITED") FOR THE PURPOSES OF UPLOADING ON THEIR WEBSITE.

In case of any revision in the Price Band, the Bid/Issue Period shall be extended for at least three additional Working Days after such revision of the Price Band, subject to the total Bid/Issue Period not exceeding ten Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company, for reasons to be recorded in writing extend the Bid/Issue Period for a minimum of one Working Day, subject to the Bid/Issue Period not exceeding ten Working Days. Any revision in the Price Band, and the revised Bid/Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges by issuing a press release and also by indicating the change on the website of the BRLM and at the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and Sponsor Bank.

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders (of which one third of the Non-Institutional Portion shall be reserved for Bidders with an application size of more than two lots and up to such lots equivalent to not more than ₹10 lakhs and two-thirds of the Non-Institutional Portion shall be reserved for Bidders with an application size exceeding ₹ 10 lakhs) and under-subscription in either of these sub-categories of Non-Institutional Portion may be allocated to Bidders in the other subcategory of Non-Institutional Portion, subject to valid Bids being received at or above the Issue Price and not less than 35% of the Net Issue shall be available for allocation to Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilize the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of Individual Bidders using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "**Issue Procedure**" beginning on page 273 of the Draft Red Herring Prospectus.

This public announcement is made in compliance with the provisions of Regulation 247(2) of the SEBI ICDR Regulations, to inform the public that our Company is proposing to undertake, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, an initial public offer of its Equity Shares of face value of ₹ 10 each pursuant to the Issue and the Draft Red Herring Prospectus dated September 30, 2025 has been filed with the SME Platform of BSE ("BSE SME") on September 30, 2025. The Draft Red Herring Prospectus filed with BSE SME shall be made public, for comments, if any, for a period of at least 21 days from the date of filing, by hosting it on the website of BSE SME at https://www.bseme.com/download/399519/SME\_IP0%20InPrinciple/RednexpharmaceuticalsDRHP\_20250930190141.pdf, on the website of the BRLM at www.hemsecurities.com and also on the website of the Company https://rednexpharma.com/. Our Company invites the public to give comments on the Draft Red Herring Prospectus filed with BSE SME with respect to disclosures made in the Draft Red Herring Prospectus. The public is requested to send a copy of the comments to the Company Secretary & Compliance Officer of our Company, and/or to the BRLM at their respective addresses mentioned below. All comments must be received by our Company and/or Company Secretary & Compliance Officer of our Company and/or to the BRLM in relation to the Issue on or before 5.00 p.m. on the 21st day from the aforementioned date of filing of the Draft Red Herring Prospectus with BSE SME.

Investments in Equity and Equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue including the risks involved. The Equity Shares issued in the Issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the Draft Red Herring Prospectus. Specific attention of the investors is invited to the section "**Risk Factors**" beginning on page 27 of the Draft Red Herring Prospectus.

Any decision to invest in the equity shares described in the Draft Red Herring Prospectus may only be taken after a Red Herring Prospectus has been filed with the ROC and must be made solely on the basis of such Red Herring Prospectus as there may be material changes in the Draft Red Herring Prospectus from the Draft Red Herring Prospectus. The equity shares, when offered through the Red Herring Prospectus, are proposed to be listed on the BSE Limited ("**BSE SME**"). For details of the share capital and capital structure of our Company and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them of our Company, see "**Capital Structure**" beginning on page 68 of the Draft Red Herring Prospectus. The liability of the members of our Company is limited. For details of the main objects of our Company as contained in our Memorandum of Association, see "**History and Corporate Structure**" beginning on page 146 of the Draft Red Herring Prospectus.

The BRLM associated with the Issue has handled 69 Public Issues in the past three years, out of which 3 Issue was closed below the Issue/ Offer Price on listing date:

Name of BRLM	Total Issue		Issue closed below IPO Price on listing date
	Mainboard	SME	
Hem Securities Limited	2	67	3 (SME)

**BOOK RUNNING LEAD MANAGER TO THE ISSUE**

**Hem Securities**

**HEM SECURITIES LIMITED**  
Address: 904, A Wing, Naman Midtown, Senapati Bapat Marg, Elphinstone Road, Lower Parel, Mumbai-400013, Maharashtra, India  
Tel. No.: +91-22-49060000;  
Email: ib@hemsecurities.com  
Investor Grievance Email redressal@hemsecurities.com  
Website: www.hemsecurities.com  
Contact Person: Roshni Lahoti; SEBI Regn. No. INM000010981

**REGISTRAR TO THE ISSUE**

**Bigshare Services Pvt. Ltd.**

**BIGSHARE SERVICES PRIVATE LIMITED**  
Address: Office No. S6-2, 6th floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri East, Mumbai-400093, Maharashtra, India  
Telephone: +91 022-6263 8200; Email: ipo@bigshareonline.com  
Investor Grievance Email: investor@bigshareonline.com  
Website: www.bigshareonline.com  
Contact Person: Mr. Babu Raphael C.  
SEBI Registration Number: INR000001385; CIN: U99999MH1994PTC076534

**COMPANY SECRETARY & COMPLIANCE OFFICER**

**REDNEX PHARMACEUTICALS LIMITED**

Rima Amitbhai Dalal

Registered Office: Survey No. 586 and 231, Near SKF Bearing, Bavla Bagodara N.H 8A, Kerala, Taluka: Bavla, Ahmedabad, Gujarat, India, 382220.

E-mail: cs@rednexpharma.com, Tel.: +91-83201-31437, Website: https://rednexpharma.com/

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Draft Red Herring Prospectus.

**REDNEX PHARMACEUTICALS LIMITED**  
On behalf of the Board of Directors  
Sd/-  
Rima Amitbhai Dalal  
Company Secretary and Compliance Officer

**Disclaimer:** Rednex Pharmaceuticals Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Draft Red Herring Prospectus on September 30, 2025. The Draft Red Herring Prospectus is available on the website of BSE SME at https://www.bseme.com/download/399519/SME\_IP0%20InPrinciple/RednexpharmaceuticalsDRHP\_20250930190141.pdf and is available on the websites of the BRLM at www.hemsecurities.com and also on the website of the Company https://rednexpharma.com/. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, see the section titled "**Risk Factors**" beginning on page 27 of the Draft Red Herring Prospectus. Potential investors should not rely on the Draft Red Herring Prospectus for making any investment decision. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "**Securities Act**") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

# ઠંડી આવતા પહેલા આ 5 વસ્તુઓ ખાવાથી વધશે તમારી રોગપ્રતિકારક શક્તિ



હાદમમાં વિટામિન ઈ, ફાઈબર અને અન્ય પોષક તત્વો હોય છે, જે રોગપ્રતિકારક શક્તિને વધારે છે. દરરોજ મૂઠ્ઠાબર હાદમ ખાવાથી માત્ર રોગપ્રતિકારક શક્તિમાં સુધારો થતો નથી, પરંતુ તેનાથી એનજી લેવલ પણ વધે છે. શિયાળામાં પલાળેલી હાદમ ખાવાથી તેના પોષક તત્વોનો શોષણ સુધારે છે.

પાલક એ વિટામિન A, C અને K નો ઉત્તમ સ્ત્રોત છે. તે એન્ટીઑક્સિડન્ટ અને બળતરા વિરોધી ગુણોથી ભરપૂર છે. શિયાળામાં સૂપ, પકાંટા અથવા સલાડના રૂપમાં પાલકનો સમાવેશ કરવાથી તમારી રોગપ્રતિકારક શક્તિને મજબૂત બનાવવામાં મદદ મળી શકે છે.

શિયાળાની ઋતુ નજીક આવી રહી છે. આ સિઝનમાં શરીરને માત્ર શારીરીક જ નહીં પરંતુ અન્ય પ્રકારના વાયરલ ઈન્ફેક્શનથી પણ બચાવવાની જરૂર છે. આ દિવસોમાં, તબીબી રોગપ્રતિકારક શક્તિ ધરાવતા લોકો જેમ કે ખાનગી, વૃદ્ધ લોકો અને લાંબા સમયથી બીમાર લોકોનું સ્વાસ્થ્ય બગાડવાનું સૌથી વધુ જોખમ રહેલું છે.

હાલમાં ઈક્ટમિન નામનું તબીબી વધારા માટે છે, જે રોગપ્રતિકારક શક્તિ વધારવા માટે જાણીતું છે. શિયાળામાં હાલમાં વધુ પુષ્ટ પુષ્ટ જે કમ્પાઉન્ડ છે. તે તમારી રોગપ્રતિકારક શક્તિમાં વધારો કરે છે. પરંતુ ઈક્ટમિન ગરમ રાખવામાં પણ મદદ કરે છે. ઈક્ટમિન અથવા શાકભાજી જેવા ખોરાકમાં હાલમાં પણ સમાવેશ કરી શકાય છે.



લીંબુ વિટામિન સીનો ઉત્તમ સ્ત્રોત છે, જે રોગપ્રતિકારક શક્તિ વધારવામાં મદદ કરે છે. આવી સ્થિતિમાં શિયાળામાં લીંબુ પાણી પીવું ખૂબ જ કમ્પાઉન્ડ છે. તે માત્ર શરીરને હાઈડ્રેટ જ રાખતું નથી, પરંતુ રોગપ્રતિકારક શક્તિને પણ મજબૂત બનાવે છે. સવારે પાણી પીવું સલામત અથવા ગરમ પાણી સાથે લીંબુ મિલું ગરમ કરી શકાય છે.

આદામાં બળતરા વિરોધી અને એન્ટીઑક્સિડન્ટ ગુણ હોય છે. તેના નિયમિત સેવનથી શરીરની રોગપ્રતિકારક શક્તિ વધવા લાગે છે. તેમને તેને આ અથવા ઉકાળાના સ્વરૂપમાં પી શકો છો. આદુનો ટુકડો ચાવવાથી પણ શિયાળામાં શારીરીક રાહત મળે છે.



## પંચાતરસ



### નારાયણ.. નારાયણ.. નારાયણ..

નારદજી તંબૂર વીણા વગાડતા વખાતા નારાયણ.. નારાયણ બોલતા બોલતા આકાશ માં ભમણ કરી રહ્યા હતા. ત્યાં અચાનક એનું ધ્યાન ધરા પરના સુંદર રાખ્યે બિહાર ની રહી યાત્રા જેમાં રસ્તા ની સાઈડ માં ઊભેલ લોકોના ટોળા દ્રુતા પાલકો ની લાંબી કાદાર વધારે હતી. બેત્રણ હેમના ની વચ્ચે નારદજી એ લાલ કવર નું કોળા ના આકાર નું તેમનું જોયું. લાલ કવર એટલા ને નિરાખર જ નારદજી ને સેવ દેખેતા ના શાક અને પોરોલા ના ટેટ ની યાદ આવી જતા પૂર્ણી ના મોઝા ડક ના દેખાટ ને વચ્ચે માં લઈ જઈ નામું નક્કી કર્યું. પ્રથમ ધ્યાનમાં ધ્યાનમાં એ સુખ નજરે જોયું તો હેન્ટમ વચ્ચે વ્યક્તિ એ તેમને નહું પણ બિહારનું બાવિયું હતું. સાચું કહું બિહારીએને એના જીવનમાં મસ્તી મજાક માં વિચર બિચર કોમ્પેડી કરવાનું મન થાય તો એક નજર બિહારના બાવિયું તરફ નજર કરવાની જરૂર છે. લાઈક માં અન્ય પાસે મોળા ની બદલે મેળવવા માટે મહેનત કરનાર નેતાઓ વિશે વિચારું છું ને તો લાલ પ્રસાદ યાદવ જેવા ખુદા મજાક મજાક માં વિચાર ની મજાક ઉડાવતા નેતા માત્ર એક જ છે. માન્યું કે એનો પ્રાણીયો વધારે હોવાના લીધે એ એને સંપૂર્ણ જગત એના સિવાય ધ્યાનમાં રાખે છે. પરંતુ સંસદ માં જેમ અભિનેત્રીની મોટીની રાખવામાં માં એન્ટ્રી થતા ઉપસ્થિત લોકો ધારમ થી પાણી થઈ જાય છે એમજ લાલજીની સ્ત્રીય માં સંસદ માં ઉપસ્થિત લોકો ઘણક મારી મારી ને પેટ પકડીને હસતા હતા. લાલજી ના ધારયારા પ્રેમ ના ના લીધે એને નિવૃત્તિ થઈ લીધી ને એના જેવી કોમ્પેડી કરવી એ અન્ય માટે અશક્ય છે.

એક માણસ મુલ્ય વાદ અનંત મારા મોઢી પસાર થઈ તો ધરનાર ના ધરનાર માં બેઠા થયા દરબારમાં અમરીયા પુરી ની જેમ ગોળ ગોળ ઊંચા કરીને ધરનાર એ માણસ ની સામું જીવનું પુછ્યું કે 'શ્રીવાડા કિત્તા આઝો. ડો.. તીન.. ચાર.. .. માણસ એ પુછ્યારાઈ ને જવાબ આપ્યો કે સરકાર લાગે છે કે ધરના ના નંબર વળી ગયા છે. અચાનક મોઢો બેઠા અચાજ ધરનાર એ માણસ ને ધમકાવવા ની યુદ્ધ માં આવતા બોલ્યા કે ધરથી વાસોલો કે જમાદા ન્યુઝ ચેનલ દેખેનકે કે ચંચલા કરને કી આદત પર ગવા છે. બોલ ક્યું બોલા બીય માં.. પાતા તુમકા હે કી બિહાર મે અચ સમોસા કો આરુ કો લાલ કી જુરુટ નહીં હે અચ દોનો બેટરા સમુદાયા ઓર કોળા કિશ્તી ઘોલ શલવ કે રાજનીતી મે વ્યસ્ત છે. અગર પત્રકાર પુછે કી બેમાણ, લાલજી રાખી જા દિન નહી રહી હે. તો જાણ્યે મિલે રહેતે કી પાપા માં કી મારોદાઈને પે યુવાન કા કામ હો રહેતે હે. મનુષ્ય પુછે યે પાત સમજ નહી આતી મી મોટીજી ધરનાર ધરનાર ધરનાર કોન બંદા લીલ રહ્યા. સમી વાચક મે એન્ટ નહી બાવે. ગરીબ કો રાશન, ગરીબ કો કપડું, ગરીબ કો પર, ગરીબ કો દવા દારૂ મુક્ત મુક્ત.. ગરીબ કો રોજગારી કી.. ના.. ના જરૂર નહી ક્યું કી મોટી સરકાર કી સંસદાર.. સાંખીને મનુષ્ય ખડમખડ હસવા લાગ્યો પણ ત્યાં અચાનક એના હાથપગ માં હકરડી પડી જતા ગમભરતો નો બોલ્યો કમા.. કમા.. કમા મરદેન માલી માંયું છું મુલ્ય થઈ ગઈ..

ધરનાર એ એટ હાસ્ય કહ્યું ને બોલ્યા. ધમલોકો માં કમા, વિનંતી, રાહોળ નથી ચાલતી. કેમ?.. મું કેમ? નજર કર સામે પૂર્ણી ની વિષ્ય મોહિની વિરોધી માંથી રાજનીતિ ના ચક્રમાં કમ્પાઈ ને ધમલોકો ની જેવ માં કે છે. વિચરતી ની બંધોમાં મુલ્ય વાદ પોઝેટ માં પકડી ને લાવી હતી. રાહોળ 'સાસ ભી કમ્પે બહુ થી સિરિવલ કેમ ' ની જેમ કરી હતી પણ ધરનાર ના દેખાટ માં આંસુ, ધન, સ્ત્રી, દારૂ ગોરે લાંબ રહેત ચાલતી નથી. મનુષ્ય નું મન અંદર થી ખૂબ અકાળ્ય ગયું ને મનમાં બોલ્યો કે પૂર્ણી પર પ્રખ્યાત ન્યુઝ ચેનલો.. ન્યુઝ પેપર એજન્સી નો મોહિલ છે. મારા ઉશારે ભલભલા રાજકર્મીઓનું સૂનું પડ્યું હતું. એ ઊંચા અચાજ રાહાર કરતા બોલ્યા કે ધરનાર, મારો પણ અચાનકીય અસુલ છે ન્યુઝ માંથી બેત્રણથી માં લઈને જનમાયું છે. રાજકર્મી, વિલ્લ ઊગાળ, બિઝનેસ મેન વગેરે ને મારા ઉશારે ડિઝો કરવાનો હતો તો તેમને ક્યાં ગાઈ ની મૂલી છે. તમારું પણ સેન્સેટિવ બહાર પાડી શકું છું મારી બાજ નજર પત્રકાર જેવી ને કલમ કરવી ના ધરા જેવી સમજે બોલીયા તો એડે ઠર..

ધરનાર એ મનુષ્ય ની કંટાળાજનક બહાક સાંખીને ને વિચર ગુપ્ત તરફ નજર કરતા ઓર આખો કે મનુષ્ય ના પાપ પુષ્ટ ની જોરકાત કરો. માર્કેટ હાથ માં લઈને વિચરુગ્રાજ બોલ્યા કે માણસ એ એના જીવન દરમિયાન 100 પાપ અને પુષ્ટ એક ક્યું છે.. જોરકાત સાંખ્યાલા જ મનુષ્ય તો ભયા ના માથો બોલ્યો કે કું યુદ્ધ સુલક અને સેવાભાવી નેતા છે. માણસ રતા રતા કાંઠાના કાંઠાવાત બોલ્યા કે નક્કી વિચરુગ્રાજ થી વંચવા માં ભલ હાથ છે. મારી જિંદગી લોકોની સેવામાં ખચાવી ઠીકી છે સો પુષ્ટ ક્યાં હશે પાપ એક જ કદાચ કદાચ મારી થયું હશે. ધરનાર એ મનુષ્ય ની એકપણ વાત સાંખ્યાલા વગર નહીં ની યાતના ની સમજ કરાવી એથી. શાશલ ના નહીં ની યાતના વિશે માણસ એ વાંચ્યું હતું એટલે એના મગજ માંથી શબ્દ બહાર ઊગ્યા ને વાચ્યા એ મોમાં પર તાળા લગાવી ઠીકા હતા. મું કરવું કેમ છુટવું? પણ યાતના થી અચાનક માણસને ધરા પર બિરાજમાન સંજ્ઞ ની મોહી પીટિયા યાતના એટલે પદ યાતના વિશે વિચારવાનું છોડી નોમોમન નક્કી કરી કે નહીં ની સાતારૂઢ વાદીને શાય અપીળા ને ત્યાં સુંઘી માં પ્રચંડ સંજ્ઞતા મેલવાઈ.. બકા, તુ દવારો તને નહી.. અચાનાતા માણસ ની નહી.. શિકાર કે છે.. ના.. રે.. ના.. લાભો ભેસ સાં અજ્ઞાનો માં ધરનાર પણ દેખાઈવાળું પર પૂરી થી એનું હાઈડર જેટ ધેનું જેવા બનાવ્યું છે. આ હાઈડર ધેનું જેવા બનાવ્યું છે. આ હાઈડર ધેનું મુદ્ધા ના ધર માં મજાક બની પાંચમાં પકડીને ધમલોક લઈ તાકાત આગળ બેંક ના લોકર પણ કદ્યું કરી યાતના ની.. લોકર ટાઈમ મેનું કરું વગેરે ભીલક સંપતિ સાથે માં મું ક્યું છે એ પની, પુત્ર, પુત્રી કે અન્ય સંબંધો પણ આતાં નથી. એટલા થયે હો વિદ્યારૂ પણ એટલા એટલે આંદન દો રમટ બોલ્યા ને. નાલો તો કરવો જ



**PUBLIC ANNOUNCEMENT**  
**Rednex Pharmaceuticals Limited**  
Rima Amithbhai Dalal

## REDNEX PHARMACEUTICALS LIMITED

Our Company was originally incorporated as a Private Limited Company under the name "Rednex Pharmaceuticals Private Limited" on December 29, 2020 under the provisions of the Companies Act, 2013 with the Registrar of Companies, Ahmedabad bearing CIN: U24304GJ2020PLC119176. Subsequently, our Company was converted into a Public Limited Company vide Special Resolution passed by the Shareholders at the Extraordinary General Meeting, held on December 30, 2024 and consequent company name was changed from "Rednex Pharmaceuticals Private Limited" to "Rednex Pharmaceuticals Limited" vide a fresh certificate of incorporation dated January 21, 2025 issued by the Registrar of Companies, Central Processing Centre bearing CIN: U24304GJ2020PLC119176. For further details of incorporation, change of registered office of our Company, please refer to chapter titled "History and Corporate Structure" beginning on page 146 of the Draft Red Herring Prospectus.

Registered Office: Survey No. 586 and 231, Near SKF Bearing, Bavla Bagodara N.H.8A, Kerala, Taluka: Bavla, Ahmedabad, Gujarat, India, 382220.  
Tel. No.: +91- 83201-31437, E-mail: info@rednexpharma.com, Website: https://rednexpharma.com  
Contact Person: Rima Amithbhai Dalal, Company Secretary & Compliance Officer  
CIN: U24304GJ2020PLC119176

**OUR PROMOTERS: CHETAN RUGNATHBHAI MATHOLIYA, JAYESHKUMAR AMARSHIBHAI SABAVA AND AKASHBHAI MANSUKHBHAI GANGADIYA**  
"THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF BSE ("BSE SME")."

### THE ISSUE

INITIAL PUBLIC OFFER OF UPTO 27,36,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH (THE "EQUITY SHARES") OF REDNEX PHARMACEUTICALS LIMITED ("OUR COMPANY" OR "THE ISSUE") AT AN ISSUE PRICE OF ₹ 10/- PER EQUITY SHARE FOR CASH, AGGREGATING UP TO ₹ (LAKHS) ("NET ISSUE") OUT OF WHICH (EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH) AT AN ISSUE PRICE OF ₹ 10/- PER EQUITY SHARE FOR CASH, AGGREGATING UP TO ₹ (LAKHS) IS RESERVED FOR SUBSCRIPTION BY ANCHOR INVESTORS TO THE ISSUE (THE "ANCHOR INVESTOR PORTION") AND THE REMAINING NET ISSUE SHALL BE RESERVED FOR SUBSCRIPTION BY OTHER BIDDERS TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF (EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH, AT AN ISSUE PRICE OF ₹ 10/- PER EQUITY SHARE FOR CASH, AGGREGATING UPTO (LAKHS) IS HEREIN REFERRED TO AS THE "NET ISSUE". THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE 26.34% AND (EQUITY SHARES) RESPECTIVELY OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DETERMINED BY OUR COMPANY IN CONSULTATION WITH THE BRLM AND WILL BE ADVERTISED IN (A) WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER AND (B) EDITION OF (C) A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER, AND GUJARATI EDITION OF (D) A REGIONAL NEWSPAPER (WHERE OUR REGISTERED OFFICE IS LOCATED), AT LEAST TWO WORKING DAYS PRIOR TO THE BID/ISSUE OPENING DATE AND SHALL BE AVAILABLE UPON THE SME PLATFORM OF BSE LIMITED ("BSE LIMITED") FOR THE PURPOSES OF UPLOADING ON THEIR WEBSITE.

Platform of BSE Limited ("BSE Limited") for the purposes of uploading on their website. The Bid/Issue Period shall be extended for at least three additional Working Days after such revision of the Price Band, subject to the total Bid/Issue Period not exceeding ten Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company, for reasons to be recorded in writing extend the Bid/Issue Period for a minimum of one Working Day. In respect of the Bid/Issue Period not exceeding ten Working Days. Any revision in the Price Band, and the revised Bid/Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges by issuing a press release and also by indicating the change on the website of the BRLM and at the terminals of the Members of the Syndicate and by indication to Designated Intermediaries and Sponsor Bank.

The issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, allocate up to at least 50% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund QIB Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders of which one-third of the Non-Institutional Portion shall be reserved for Bidders with an application size of more than two lots and up to such lots equivalent to not more than ₹10 lakhs and two-thirds of the Non-Institutional Portion shall be reserved for Bidders with an application size exceeding ₹ 10 lakhs and under-subscription in either of these sub-categories of Non-Institutional Portion may be allocated to Bidders in the other subcategory of Non-Institutional Portion, subject to valid bids being received at or above the Issue Price and not less than 35% of the Net Issue shall be available for allocation to Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilize the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of Individual Bidders using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 273 of the Draft Red Herring Prospectus.

This public announcement is made in compliance with the provisions of Regulation 24(2)(c) of the SEBI ICDR Regulations, to inform the public that our Company is proposing to undertake, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, an initial public offer of its Equity Shares of face value of ₹ 10 each pursuant to the Issue and the Draft Red Herring Prospectus dated September 30, 2025 has been filed with the SME Platform of BSE ("BSE SME") on September 30, 2025. The Draft Red Herring Prospectus filed with BSE SME shall be made public, for comments, if any, for a period of at least 21 days from the date of filing, by hosting it on the website of BSE SME at https://www.bseindia.com/download/399519/SME\_IPO%20PrincipleRednexpharmaceuticalsDRHP\_20250930190141.pdf, on the website of the BRLM at www.hemsecurities.com and also on the website of the Company https://rednexpharma.com. Our Company invites the public to give comments on the Draft Red Herring Prospectus filed with BSE SME with respect to disclosures made in the Draft Red Herring Prospectus. The public is requested to send a copy of the comments to the Company Secretary & Compliance Officer of our Company, and/or to the BRLM at their respective addresses mentioned below. All comments must be received by our Company and/or Company Secretary & Compliance Officer of our Company and/or to the BRLM in relation to the Issue on or before 5:00 p.m. on the 21st day from the aforementioned date of filing of the Draft Red Herring Prospectus with BSE SME.

Investments in Equity and Equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of the Company and the Issue including the risks involved. The Equity Shares issued in the Issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the Draft Red Herring Prospectus. Specific attention of the investors is invited to the section "Risk Factors" beginning on page 27 of the Draft Red Herring Prospectus.

Any decision to invest in the equity shares described in the Draft Red Herring Prospectus may only be taken after a Red Herring Prospectus has been filed with the ROC and must be made solely on the basis of such Red Herring Prospectus as there may be material changes in the Red Herring Prospectus from the Draft Red Herring Prospectus. The equity shares, when offered through the Red Herring Prospectus, are proposed to be listed on the BSE Limited ("BSE SME"). For details of the share capital and capital structure of our Company and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them on or after the date of filing of the Draft Red Herring Prospectus, see "Capital Structure" beginning on page 68 of the Draft Red Herring Prospectus. The liability of the members of our Company is limited. For details of the main objects of our Company as contained in our Memorandum of Association, see "History and Corporate Structure" beginning on page 146 of the Draft Red Herring Prospectus.

The BRLM associated with the Issue has handled 69 Public Issues in the past three years, out of which 3 issue was closed below the Issue/ Offer Price on listing date:

Name of BRLM	Total Issue		Issue closed below IPO Price on listing date
	Mainboard	SME	
Hem Securities Limited	2	67	3 (SME)

**BOOK RUNNING LEAD MANAGER TO THE ISSUE**  
**REGISTRAR TO THE ISSUE**

**Hem Securities**  
HEM SECURITIES LIMITED  
Address: 904, A Wing, Naman Midtown, Senapati Bapat Marg, Elphinstone Road, Lower Parel, Mumbai-400013, Maharashtra, India  
Tel. No.: +91- 22- 49600000  
Email: info@hemsecurities.com  
Investor Grievance Email: redessal@hemsecurities.com  
Website: www.hemsecurities.com  
Contact Person: Roshni Lahori, SEBI Regn. No. INM000010981

**Bigshare Services Pvt. Ltd.**  
BIGSHARE SERVICES PRIVATE LIMITED  
Address: Office No. S6-2, 6th floor, Pinnacle Business Park, Next to Ahura Centre, Mahalkai Cross Road, Andheri East, Mumbai-400093, Maharashtra, India  
Telephone: +91 022-6263 8200; Email: ipo@bigshareonline.com  
Investor Grievance Email: investor@bigshareonline.com  
Website: www.bigshareonline.com  
Contact Person: Mr. Babu Rajpal Ch. SEBI Registration Number: INR000001385; CIN: U99999MH1994FTC076534

**COMPANY SECRETARY & COMPLIANCE OFFICER**  
**REDNEX PHARMACEUTICALS LIMITED**  
Rima Amithbhai Dalal  
Registered Office: Survey No. 586 and 231, Near SKF Bearing, Bavla Bagodara N.H.8A, Kerala, Taluka: Bavla, Ahmedabad, Gujarat, India, 382220.  
E-mail: cs@rednexpharma.com, Tel.: +91- 83201-31437, Website: https://rednexpharma.com/

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Draft Red Herring Prospectus.

Place: Ahmedabad, Gujarat  
Date: October 01, 2025  
Rima Amithbhai Dalal  
Company Secretary and Compliance Officer

**Disclaimer:** Rednex Pharmaceuticals Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to issue an initial public offer of its Equity Shares and has filed the Draft Red Herring Prospectus on September 30, 2025. The Draft Red Herring Prospectus is available on the website of BSE SME at https://www.bseindia.com/download/399519/SME\_IPO%20PrincipleRednexpharmaceuticalsDRHP\_20250930190141.pdf and is available on the websites of the BRLM at www.hemsecurities.com and also on the website of the Company https://rednexpharma.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, see the section titled "Risk Factors" beginning on page 27 of the Draft Red Herring Prospectus. Potential investors should not rely on the Draft Red Herring Prospectus for making any investment decision. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so stated, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.